Core Viewpoint - Fulgent Genetics reported better-than-expected Q2 2025 results, with significant revenue growth and a raised full-year revenue outlook, despite a wider GAAP loss due to a one-time impairment [1][11]. Financial Performance - Q2 2025 GAAP revenue was $81.8 million, exceeding the analyst consensus estimate of $76.2 million, representing a 15.2% year-over-year increase from $71.0 million in Q2 2024 [2]. - Non-GAAP earnings per share were $0.07, outperforming the anticipated $(0.18) loss, although this reflects a 53.3% decline from $0.15 in Q2 2024 [2]. - Non-GAAP gross margin improved to 44.2%, up from 40.1% in the prior year [2]. - Adjusted EBITDA was a loss of $3.0 million, widening from a loss of $0.7 million in the same period last year [2]. - Total liquidity was $777.5 million, supporting ongoing investments and potential share repurchases [10]. Business Segments - The Laboratory Services segment drove the majority of revenue, with core revenue reaching $81.7 million, up 16% year-over-year, primarily due to reproductive health diagnostics and strong legacy test volumes [5]. - The Therapeutic Development segment is advancing clinical trials for cancer drug candidates, with FID-007 in phase 2 and FID-022 entering phase 1, indicating long-term growth potential [7]. - The biopharma services division expanded its offerings, with revenue from anatomic pathology returning to year-over-year growth after investments in digital systems [8]. Strategic Initiatives - Significant investments in digital pathology and AI are enhancing productivity and improving turnaround times for laboratory workflows [6]. - The company is focusing on product innovation, expanding partnerships, and compliance with healthcare regulations to meet market demands [4]. Future Outlook - Management raised the FY2025 core revenue outlook to $320 million, citing strong order momentum and new client wins [11]. - The company expects a GAAP loss of approximately $(2.10) per share for FY2025, reflecting the one-time impairment, and a smaller non-GAAP loss of $(0.35) per share [11].